Tenofovir alafenamide semi-tartrate

A technology of tenofovir alafenamide and hemi-tartrate, which is applied in the field of tenofovir alafenamide hemi-tartrate, can solve the problems that tenofovir alafenamide has not been reported, and improve the purity and yield, improved chemical stability, and good crystallization properties

Active Publication Date: 2015-09-23
HANGZHOU HEZE PHARMA TECH +2
View PDF6 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] But there is no report of other pharmaceutically acceptable salts of tenofovir alafenamide

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tenofovir alafenamide semi-tartrate
  • Tenofovir alafenamide semi-tartrate
  • Tenofovir alafenamide semi-tartrate

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Example 1: Preparation of tenofovir alafenamide hemitartrate

[0036]Add 9-[(R)-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl] to the reactor equipped with stirrer Methoxy]propyl]adenine (5.00 g), tartaric acid (1.56 g), ethanol (30 ml) and acetonitrile (20 mL). The mixture was heated to 70°C-75°C to dissolve the solids. After filtration, the filtrate was cooled to 0°C-5°C over 4 hours. The temperature was maintained for 1-18 hours, and the resulting slurry was filtered and washed with 0.2 mL of acetonitrile (0°C-5°C). The solid was dried at 50° C. under vacuum to obtain 3.14 g of tenofovir alafenamide hemitartrate, yield: 48%, and its HPLC purity was 99.65% (area normalization method).

Embodiment 2

[0037] Example 2: Preparation of tenofovir alafenamide hemitartrate

[0038] Add 9-[(R)-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl] to the reactor equipped with stirrer Methoxy]propyl]adenine (5.00 g), L-tartaric acid (1.56 g), ethanol (30 ml) and acetonitrile (20 mL). The mixture was heated to 70°C-75°C to dissolve the solids. After filtration, the filtrate was cooled to 0°C-5°C over 4 hours. The temperature was maintained for 1-18 hours, and the resulting slurry was filtered and washed with 0.2 mL of acetonitrile (0°C-5°C). The solid was dried under vacuum at 50°C to obtain 6.30 g of tenofovir alafenamide hemitartrate, yield: 96%, and its HPLC purity was 99.75% (area normalized method).

Embodiment 3

[0039] Example 3: Preparation of tenofovir alafenamide hemitartrate

[0040] Add 9-[(R)-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl] to the reactor equipped with stirrer Methoxy]propyl]adenine (5.00 g), L-tartaric acid (1.56 g), methanol (30 ml) and diethyl ether (20 mL). The mixture was heated to 70°C-75°C to dissolve the solids. After filtration, the filtrate was cooled to 0°C-5°C over 4 hours. The temperature was maintained for 1-18 hours, and the resulting slurry was filtered and washed with 0.2 mL of acetonitrile (0°C-5°C). The solid was dried at 50° C. under vacuum to obtain 6.26 g of tenofovir alafenamide hemitartrate, yield: 95%, and its HPLC purity was 99.68% (area normalization method).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a novel pharmaceutically acceptable salt of tenofovir alafenamide, and the 9-[(R)-2-[[(S)-[[(S)-1-(isopropionic carbonyl)ethyl]amino]phenoxylphosphinyl]methoxy]propyl]adenine semi-tartrate. The salt has modified chemical stability and thermal stability, and has a relatively high melting point. The salt is more suitable to be used as a raw materials medicine. Also, the salt has excellent crystallinity. The salt can be prepared with a convenient method, and purity and yield are further improved. The salt is suitable for large-scale industrialized productions.

Description

technical field [0001] The present invention relates to the following formula (I) The compound represented (chemical name: 9-[(R)-2-[[(S)-[[(S)-1-(isopropionic acid carbonyl) ethyl] amino] phenoxyphosphinyl] methoxy propyl]propyl]adenine hemitartrate, hereinafter sometimes referred to simply as "tenofovir alafenamide hemitartrate"), an experimental novel prodrug for the treatment of AIDS and HBV infection. Background technique [0002] Tenofovir alafenamide (tenofovir alafenamide, TAF, GS-7340, CAS: 379270-37-8), the original research Gilead Sciences (Gilead Sciences), the drug is an experiment of tenofovir (tenofovir) It is a novel prodrug, which is mainly used in the treatment of AIDS (HIV) infection and hepatitis B virus infection. [0003] The current patent CN1291994C / US7803788 reports a series of general formula compounds including the structure of tenofovir alafenamide, and also describes the monofumarate of tenofovir. Patents WO2013025788 and CN201280039891.0 de...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07F9/6561A61K31/675A61P31/20A61P31/18
Inventor 倪晟毛建峰陈鸿翔姜维斌赵航盛荣周亮陈琳萍
Owner HANGZHOU HEZE PHARMA TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products